Author

Vinod Parameswaran

Observed names: Parameswaran, Vinod, V . Parameswaran, V. Parameswaran

Institutions: Avera Health, Avera McKennan Hospital & University Health Center

Observed institutions: Avera Health, Avera McKennan Hospital & University Health Center

OpenAlex ID: A5089051667

Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing

2022 · Muna Qayed, Joseph P. McGuirk, et al. · Cytotherapy · 84

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

2018 · Michael A. Pulsipher, Brent R. Logan, et al. · Haematologica · 25

Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial

2024 · Vikas Gupta, Abdulraheem Yacoub, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20

ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).

2023 · Ian W. Flinn, Caron Alyce Jacobson, et al. · Journal of Clinical Oncology · 14

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

2021 · Vikas Gupta, Abdulraheem Yacoub, et al. · Blood · 14

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

2022 · Vikas Gupta, Abdulraheem Yacoub, et al. · Blood · 13

P1042: Safety and Tolerability Results From the Phase 3b Freedom Trial of Fedratinib (fedr), an Oral, Selective Jak2 Inhibitor, in Patients With Myelofibrosis (mf) Previously Treated With Ruxolitinib (rux)

2022 · V. Gupta, A. Yacoub, et al. · HemaSphere · 5

Atovaquone-Proguanil: A Promising Therapy for Persistent Relapsing Babesiosis

2024 · Mahum Shahid, Brendan Wechsler, et al. · Case Reports in Infectious Diseases · 2

P1107: Zuma-22: a Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-care Therapy in Patients With Relapsed or Refractory Follicular Lymphoma

2023 · Ian W. Flinn, Caron Jacobson, et al. · HemaSphere · 2

Zuma‐22: a Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel (axi‐cel) Vs Standard‐of‐care Therapy in Patients With Relapsed/refractory Follicular Lymphoma

2023 · I. W. Flinn, C. A. Jacobson, et al. · Hematological Oncology · 1

MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

2020 · Vikas Gupta, Abdulraheem Yacoub, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe)

2018 · Michael Pulsipher, Brent R. Logan, et al. · SSRN Electronic Journal · 1

Induction R2 Followed by Maintenance in Patients With Relapsed/refractory Transformed Follicular Lymphoma: Interim Analysis From the Phase 3b Magnify Study

2021 · F . Lansigan, V . Parameswaran, et al. · Hematological Oncology

Works count: 14

Citation count: 182

H-index: 6

I10-index: 6